Macrocyclic peptides in drug discovery
October 2022
Technion-Israel Institute of Technology, Haifa, Israel(1)
The University of Tokyo, Tokyo, Japan(2)
The University of Tokyo, Tokyo, Japan(2)
Developing an effective binder for a specific ubiquitin (Ub) chain is a promising approach for modulating various biological processes with potential applications in drug discovery. Here, the researchers combine the Random Non-standard Peptides Integrated Discovery (RaPID) method and chemical protein synthesis to screen an extended library of macrocyclic peptides and to discover a specific binder for this Ub chain. The authors present a powerful strategy for the selective inhibition of protein-protein interactions using cyclic peptides. This study offers an advancement in modulating central Ub pathways and provides opportunities in drug discovery areas associated with Ub signalling.
Selective macrocyclic peptide modulators of Lys63-linked ubiquitin chains disrupt DNA damage repair
Ashraf Brik(1), Hiroaki Suga(2)
Added on: 03-15-2023
[1] https://www.nature.com/articles/s41467-022-33808-6[2] https://www.drugtargetreview.com/news/106515/peptides-with-anticancer-potential-discovered-in-new-study/
